Cerus Corporation and the Swiss Red Cross Renew Commercial Contract With a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has renewed its contract with the Transfusion Service of the Swiss Red Cross (Blutspende SRK Schweiz) by entering into a five-year purchase agreement for the INTERCEPT Blood System for platelets.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC